Fast Five Quiz: Key Aspects of Metastatic Breast Cancer

Elwyn C. Cabebe, MD

Disclosures

August 10, 2020

Treatment with a single endocrine agent is usually continued until disease progression. Considerations are as follows:

  • AIs have been shown to be more effective than tamoxifen for adjuvant therapy and metastatic disease.

  • Patients who have relapse or have progressive disease on tamoxifen may be switched to an AI.

  • Patients who have relapse or progression of disease while receiving a nonsteroidal AI (eg, anastrozole or letrozole) may be changed to a steroidal AI (eg, exemestane) or a selective ER-downregulator (eg, fulvestrant).

  • The fulvestrant regimen is 500 mg intramuscularly on days on days 1, 15, and 29 and once monthly thereafter or in combination with palbociclib (125 mg orally once daily, days 1-21).

  • Optionally, consider the androgenic agent fluoxymesterone (10 mg orally twice daily) or the progestational agent megestrol acetate (40 mg orally four times daily) or estradiol (2 mg orally twice daily).

  • Systemic chemotherapy should be reserved for patients with hormone-insensitive disease or those with symptomatic hormone-sensitive disease who have not responded to any hormone therapy options or who are moderately to severely symptomatic and in urgent need of symptom palliation.

  • The options for cytotoxic-containing chemotherapy include single-agent therapy and combination cytotoxic therapy.

Learn more about endocrine therapy in postmenopausal women with metastatic breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....